PT4069232T - Masupirdina para tratar sintomas comportamentais e psicológicos na demência - Google Patents
Masupirdina para tratar sintomas comportamentais e psicológicos na demênciaInfo
- Publication number
- PT4069232T PT4069232T PT208290080T PT20829008T PT4069232T PT 4069232 T PT4069232 T PT 4069232T PT 208290080 T PT208290080 T PT 208290080T PT 20829008 T PT20829008 T PT 20829008T PT 4069232 T PT4069232 T PT 4069232T
- Authority
- PT
- Portugal
- Prior art keywords
- dementia patients
- psychological symptoms
- treating behavioral
- behavioral
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201941049516 | 2019-12-02 | ||
| IN201941049517 | 2019-12-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT4069232T true PT4069232T (pt) | 2026-01-26 |
Family
ID=74003821
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT208290080T PT4069232T (pt) | 2019-12-02 | 2020-12-02 | Masupirdina para tratar sintomas comportamentais e psicológicos na demência |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20220409614A1 (pt) |
| EP (1) | EP4069232B1 (pt) |
| JP (1) | JP7556031B2 (pt) |
| KR (1) | KR20220108123A (pt) |
| CN (1) | CN114901282B (pt) |
| AU (1) | AU2020398082A1 (pt) |
| BR (1) | BR112022010493A2 (pt) |
| CA (1) | CA3162952C (pt) |
| DK (1) | DK4069232T3 (pt) |
| ES (1) | ES3059972T3 (pt) |
| FI (1) | FI4069232T3 (pt) |
| HR (1) | HRP20260078T1 (pt) |
| IL (1) | IL293416A (pt) |
| LT (1) | LT4069232T (pt) |
| MA (1) | MA57829B1 (pt) |
| MX (1) | MX2022006535A (pt) |
| PL (1) | PL4069232T3 (pt) |
| PT (1) | PT4069232T (pt) |
| RS (1) | RS67679B1 (pt) |
| SI (1) | SI4069232T1 (pt) |
| SM (1) | SMT202600019T1 (pt) |
| WO (1) | WO2021111330A1 (pt) |
| ZA (1) | ZA202206042B (pt) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4559230B2 (ja) | 2002-11-28 | 2010-10-06 | スベン ライフ サイエンシズ リミティド | セロトニン受容体に対する親和性を有する新規ｎ−アリールスルホニル−３−置換されたインドール、その調製方法、それを含有する医薬組成物 |
| TW200531680A (en) | 2004-03-03 | 2005-10-01 | Merz Pharma Gmbh & Co Kgaa | Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease |
| KR20140041670A (ko) * | 2011-06-03 | 2014-04-04 | 엘란 파마슈티컬스, 엘엘씨 | 행동 장애 및 정신 장애의 치료를 위한 실로―이노시톨 |
| HUE036008T2 (hu) | 2013-12-02 | 2018-06-28 | Suven Life Sciences Ltd | Eljárás 1-[(2-brómfenil)szulfonil]-5-metoxi-3-[(4-metil-1-piperazinil)metil]-1H-indol-dimezilát-monohidrát nagyüzemi léptékben történõ elõállítására |
| EP3458040B1 (en) * | 2016-05-18 | 2021-01-27 | Suven Life Sciences Limited | Combination of pure 5-ht6 receptor antagonists with nmda receptor antagonist |
| DK3458039T3 (da) * | 2016-05-18 | 2020-09-14 | Suven Life Sciences Ltd | Tripelkombination af rene 5-ht6-receptorantagonister, acetylcholinesterasehæmmere og nmda-receptorantagonist |
| EA036347B1 (ru) * | 2016-05-18 | 2020-10-29 | Сувен Лайф Сайенсиз Лимитед | Комбинация чистых антагонистов 5-ht6 рецепторов с ингибиторами ацетилхолинэстеразы |
| CN110799189A (zh) | 2017-07-03 | 2020-02-14 | 苏文生命科学有限公司 | 纯5-ht6受体拮抗剂的新用途 |
-
2020
- 2020-12-02 AU AU2020398082A patent/AU2020398082A1/en active Pending
- 2020-12-02 LT LTEPPCT/IB2020/061383T patent/LT4069232T/lt unknown
- 2020-12-02 ES ES20829008T patent/ES3059972T3/es active Active
- 2020-12-02 BR BR112022010493A patent/BR112022010493A2/pt unknown
- 2020-12-02 CA CA3162952A patent/CA3162952C/en active Active
- 2020-12-02 EP EP20829008.0A patent/EP4069232B1/en active Active
- 2020-12-02 SM SM20260019T patent/SMT202600019T1/it unknown
- 2020-12-02 US US17/780,734 patent/US20220409614A1/en active Pending
- 2020-12-02 KR KR1020227022173A patent/KR20220108123A/ko active Pending
- 2020-12-02 PT PT208290080T patent/PT4069232T/pt unknown
- 2020-12-02 RS RS20260069A patent/RS67679B1/sr unknown
- 2020-12-02 CN CN202080090893.7A patent/CN114901282B/zh active Active
- 2020-12-02 IL IL293416A patent/IL293416A/en unknown
- 2020-12-02 DK DK20829008.0T patent/DK4069232T3/da active
- 2020-12-02 SI SI202030716T patent/SI4069232T1/sl unknown
- 2020-12-02 HR HRP20260078TT patent/HRP20260078T1/hr unknown
- 2020-12-02 MX MX2022006535A patent/MX2022006535A/es unknown
- 2020-12-02 WO PCT/IB2020/061383 patent/WO2021111330A1/en not_active Ceased
- 2020-12-02 FI FIEP20829008.0T patent/FI4069232T3/fi active
- 2020-12-02 PL PL20829008.0T patent/PL4069232T3/pl unknown
- 2020-12-02 MA MA57829A patent/MA57829B1/fr unknown
- 2020-12-02 JP JP2022532840A patent/JP7556031B2/ja active Active
-
2022
- 2022-05-31 ZA ZA2022/06042A patent/ZA202206042B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3162952C (en) | 2024-06-11 |
| JP7556031B2 (ja) | 2024-09-25 |
| WO2021111330A1 (en) | 2021-06-10 |
| BR112022010493A2 (pt) | 2022-09-06 |
| ZA202206042B (en) | 2024-09-25 |
| MA57829B1 (fr) | 2026-02-27 |
| ES3059972T3 (en) | 2026-03-24 |
| CN114901282B (zh) | 2024-06-25 |
| LT4069232T (lt) | 2026-02-10 |
| HRP20260078T1 (hr) | 2026-04-10 |
| KR20220108123A (ko) | 2022-08-02 |
| JP2023506724A (ja) | 2023-02-20 |
| MX2022006535A (es) | 2022-09-09 |
| US20220409614A1 (en) | 2022-12-29 |
| AU2020398082A1 (en) | 2022-06-16 |
| FI4069232T3 (fi) | 2026-02-10 |
| IL293416A (en) | 2022-07-01 |
| SMT202600019T1 (it) | 2026-03-09 |
| PL4069232T3 (pl) | 2026-03-16 |
| DK4069232T3 (da) | 2026-01-26 |
| EP4069232A1 (en) | 2022-10-12 |
| RS67679B1 (sr) | 2026-02-27 |
| EP4069232B1 (en) | 2025-12-24 |
| CA3162952A1 (en) | 2021-06-10 |
| CN114901282A (zh) | 2022-08-12 |
| SI4069232T1 (sl) | 2026-04-30 |
| AU2020398082A8 (en) | 2022-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273820A (en) | Systems and methods to ensure data security of treatment methods for diseases and disorders that use digital therapies | |
| IL268327A (en) | A pharmaceutical preparation for use in the treatment and prevention of c5-related diseases and methods for the treatment and prevention of c5-related diseases | |
| IL264301A (en) | Treatment of Fabry disease in ert-naive and ert-experienced patients | |
| PL4014976T3 (pl) | Aprocitentan do stosowania w leczeniu nadciśnienia tętniczego i chorób z nim związanych w połączeniu z walsartanem | |
| IL289167A (en) | The history of 2h-indazole and their use in the treatment of diseases | |
| LT3544619T (lt) | Nervinio audinio vienetas ir tokio vieneto naudojimas implantavimui į žinduolio nervų sistemą | |
| SG10202002898RA (en) | A Pharmaceutical Composition For Use In The Treatment Or Prevention Of A C5-Related Disease And A Method For Treating Or Preventing A C5-Related Disease | |
| SG11202000423XA (en) | Treatment of fabry disease in ert-naïve and ert-experienced patients | |
| GB2583322B (en) | Method for managing behavioral treatment therapy and devices thereof | |
| ZA202007317B (en) | Methods of treating patients at risk for renal injury and renal failure | |
| IL243510B (en) | A combination of oxycodone and naloxone for the treatment of pain in patients suffering from pain and a disease that causes intestinal dysbiosis and/or increases the risk of intestinal bacterial translocation | |
| GB2574747B (en) | Use of lambda interferons in the treatment of obesity-related disorders and related diseases | |
| PT4069232T (pt) | Masupirdina para tratar sintomas comportamentais e psicológicos na demência | |
| IL282965A (en) | Electronic devices and treatment methods using antipsychotic drugs in combination with digital therapies | |
| EP4065188A4 (en) | User interface monitoring and verification thereof in medical treatment systems | |
| PT4069231T (pt) | Combinações de masupirdina com donepezilo ou memantina para tratamento de sintomas comportamentais e psicológicos em pacientes com demência | |
| PL3937948T3 (pl) | Fitoekdyzony i ich pochodne do ich zastosowania w leczeniu chorób nerwowo-mięśniowych | |
| PL3713590T3 (pl) | Ludzka beta 2 defensyna do stosowania w zapobieganiu i leczeniu choroby przeszczep przeciwko gospodarzowi | |
| IL288905A (en) | diagnosis and treatment | |
| IL290912A (en) | Preparations for the treatment of brain damage and neurodegenerative diseases | |
| GB201706722D0 (en) | Diagnostic methods and treatment in equine disease | |
| GB201521358D0 (en) | A method for the treatment and/or reduction of inflammation in a subject and diagnostic method thereof |